Strategic Board Ourself has recently expanded its leadership with multiple high-profile board appointments (Marla Beck, Brent Saunders, Dayna Quanbeck) and a CEO transition in 2022, signaling a strong governance focus and potential for partnerships with strategic investors or executive-level sponsorships to accelerate market reach.

Innovative Delivery The company emphasizes a patented, advanced subtopical skin delivery system designed to deliver results without needles, creating a unique value proposition that can be leveraged in collaborations with dermatology clinics, medspa networks, and cosmeceutical distributors seeking differentiated SKUs.

Growth Funding With substantial funding totaling over $113M and revenue in the low tens of millions, there is visible capital availability for channel expansion, co-development deals, or scaled marketing collaborations to accelerate market penetration.

Post‑COVID Momentum Launch timing during post-COVID consumer uncertainty suggests resilience and adapting consumer demand patterns; opportunities exist to engage DTC and retail partners focused on wellness, sustainable skincare routines, and simplified regimens.

Market Positioning As a subtopical skincare brand under GLO Pharma with a focus on rapid visible results and all-in-one products, there are potential sales avenues with professional channels (dermatology offices, medical spas) and prestige beauty retailers seeking innovative, science-backed delivery systems.